Oxiplat 50 Injection: Each vial contains 10ml solution containing Oxaliplatin USP 50mg(5mg/ml).
Oxiplat 100 Injection: Each vial contains 20ml solution containing Oxaliplatin USP 100mg (5mg/ml).
Oxiplat 200 Injection: Each vial contains 40ml solution containing Oxaliplatin USP 200mg (5mg/ml).
DESCRIPTION: Oxaliplatin is slightly soluble in water, very slightly soluble in methanol and practically insoluble in ethanol.
Mechanism Of Action: Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter-and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and ranscription. Cytotoxicity is cell-cycle nonspecific. In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. In combination with 5-fluorouracil, oxaliplatin exhibits in vitro and in vivo antiproliferative activity greater than either compound alone in several tumor models [HT29 (colon), GR (mammary), and L1210 (leukemia)].
INDICATIONS: Oxaliplatin, used in combination with infusional 5-fluorouracil/folinic acid, is indicated for: • Adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. • Treatment of advanced colorectal cancer.
DOSAGE AND ADMINISTRATION:
Dosage: Administer oxaliplatin in combination with 5-fluorouracil/folinic acid every 2 weeks. For advanced disease, treatment is recommended until disease progression or unacceptable toxicity. For adjuvant use, treatment is recommended for a total of 6 months (12 cycles). Day 1: Oxaliplatin 85 mg/m² intravenous infusion in 250-500 mL 5% Dextrose injection, USP and folinic acid 200 mg/m² intravenous infusion in 5% Dextrose Injection, USP both given over 120 minutes at the same time in separate bags using a Y-line, followed by 5-fluorouracil 400 mg/m² intravenous bolus given over 2-4 minutes, followed by 5-fluorouracil 600 mg/m² intravenous infusion in 500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous infusion. Day 2: Folinic acid 200 mg/m² intravenous infusion over 120 minutes, followed by 5-fluorouracil 400 mg/m² intravenous bolus given over 2-4 minutes, followed by 5-fluorouracil 600 mg/m² intravenous infusion in 500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous infusion.
Use in Pregnancy: Pregnancy Category D.
Packing : Oxiplat 50 Injection: Each box contains 1 vial of 10ml solution.
Oxiplat 100 Injection: Each box contains 1 vial of 20ml solution.
Oxiplat 200 Injection: Each box contains 1 vial of 40ml solution.